ONS Leaders Named to Biden Cancer Initiative Board and Advisory Committee
ONS President Susan Schneider, PhD, RN, AOCN®, FAAN, was appointed to the Biden Cancer Initiative board of directors, among other experts in health care, business, finance, and technology. The Cancer Initiative also named ONS Chief Executive Officer Brenda Nevidjon MSN, RN, FAAN, to its advisory committee, comprised of 25 other experts aiming to transform the way cancer is detected, diagnosed, and treated by implementing new solutions to complex healthcare problems.
- Read more about ONS Leaders Named to Biden Cancer Initiative Board and Advisory Committee
- Add new comment
Get an Overview of Radiation Therapy for Cancer
Radiation therapy is a precise cancer treatment that targets tumor cells specifically and spares healthy surrounding tissues. Contrary to pharmacologic treatment methodologies, side effects are predominantly site-specific.
FDA Approves Abemaciclib As Initial Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer
On February 26, 2018, the U.S. Food and Drug Administration (FDA) approved abemaciclib (Verzenio™) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 HER2-negative advanced or metastatic breast cancer.
- Read more about FDA Approves Abemaciclib As Initial Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer
- Add new comment
How One ONS Chapter Is Providing Education on New Drug Approvals
With more than 50 new U.S. Food and Drug Administration approvals for cancer therapy in 2017 alone, oncology nurses are challenged about how to keep up with all of the latest practice updates. However, the Philadelphia Area Chapter of the Oncology Nursing Society (PACONS) leadership has taken an active role in helping to ensure their chapter members are given the evidence-based cancer treatment information they need to improve their practice.
The Case of the Cancer Genetics Referral
Christina is a 29-year-old African American woman with a strong family history of breast and ovarian cancers and a personal history of benign ovarian fibroids. She was referred to your office because of a suspicious lump in her left breast. Because of her family history, Christina is especially worried. You are concerned that Christina could have a hereditary family cancer syndrome, and you know that a comprehensive family history must be obtained.
Prevent and Treat Venous Thromboembolism in Patients With Cancer
Venous thromboembolism (VTE), namely deep vein thrombosis and pulmonary embolism, is a common and serious complication. VTE is the second-leading cause of death in patients with cancer and has been connected to poorer prognoses. Other consequences include reduced short- and long-term mortality, increased risk for recurrent VTE and bleeding, a threefold increase in hospitalizations, and higher total healthcare costs. Advance practice nurses (APNs) must understand prevention strategies and treatment guidelines for this serious complication.
FDA Approves Durvalumab After Chemoradiation for Unresectable Stage III NSCLC
On February 16, 2018, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
- Read more about FDA Approves Durvalumab After Chemoradiation for Unresectable Stage III NSCLC
- Add new comment
2018 U.S. Budget Agreement Contains Key Wins for ONS—Plus an Area of Concern
The U.S. Congress continued its budget pattern in February, enacting another extension of the 2017 budget agreement into law on February 8, 2018. The current iteration of the budget law will raise caps on defense and non-defense spending over two years and keep the federal government running through March 23, but more importantly, it includes the following provisions of special interest to ONS.
- Read more about 2018 U.S. Budget Agreement Contains Key Wins for ONS—Plus an Area of Concern
- Add new comment
FDA Approves Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
On February 14, 2018, the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada) for patients with non-metastatic castration-resistant prostate cancer.
- Read more about FDA Approves Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
- Add new comment
Search the Literature to Critically Appraise Evidence
Changes in technology have brought about significant opportunities in how we identify and manage information. We have access to published research and clinical articles from thousands of journals to answer clinical questions. Finding the right information can be challenging, but building your skills in searching for evidence and synthesizing evidence is critical to becoming an evidence-based practice expert. Here’s how to proceed.